We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.
The healthcare sector anticipates a resurgence in M&A activity by 2025, bolstered by improved economic conditions and reduced regulatory hurdles.
Metsera aims to go public on Nasdaq, capitalizing on strong equity markets and growing demand for weight-loss solutions, backed by ARCH Venture Partners.
Gilead Sciences partners with LEO Pharma to develop STAT6-based therapies for inflammatory diseases, aiming to enhance patient care with new treatment options.
Biogen plans to acquire Sage Therapeutics, boosting Sage's stock by 34%. This move underscores key market shifts in pharmaceuticals.
Virta Health reports a 60% revenue increase in 2024 by providing nutrition programs as an alternative to costly drugs, appealing to employers focused on sustainable solutions.
Walgreens reports better-than-expected earnings with strategic moves boosting sales, despite net losses and ongoing challenges.
Discover how Eli Lilly's Zepbound received Medicare coverage for sleep apnea, offering new treatment possibilities for millions of Americans.
Walgreens Boots Alliance faces analyst skepticism ahead of its earnings report, with mixed ratings and potential acquisition talks casting uncertainty over its stock performance.
Novo Nordisk shares rise post-UBS upgrade, reflecting positive sentiment in the weight-loss drug market despite recent challenges.
Roche enhances its biopharmaceutical capabilities with the acquisition of Poseida Therapeutics, securing a stronger position in the gene therapy market.
Moderna's shares increased by over 10% due to progress in H5N1 vaccine development following a human fatality in the U.S.
Johnson & Johnson's new lung cancer regimen, Rybrevant and Lazcluze, shows a notable survival advantage over AstraZeneca's Tagrisso, sparking hope for better patient outcomes.
119
